Given the excellent efficacy of anti-PD1/PDL1 against advanced NSCLC, researchers further evaluated the effectiveness of anti-PD1/PDL1 antibodies as adjuvant treatment for stages I–III NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.